Open-label Phase II Trial of Adjuvant bishRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer

Trial ID # NCT01309230
Phase II
Drug Class Immunotherapy: Vaccine/TGFbeta
Drug Name Gemogenovatucel-T
Alternate Drug Names Vigil, bi-shRNA-furin/GMCSF-expressing autologous tumor cell vaccine, bi-shRNA-furin and granulocyte macrophage colony stimulating factor augmented autologous tumor cell vaccine, FANG vaccine
Drugs in Trial Gemogenovatucel-T
Eligible Participant

Stage III/IV disease with no evidence of active disease after first-line therapy

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Randomized


RFS, evaluated per RECIST


FANG maint vs Placebo:

RFS (from time of procurement): mean/median: 27.5/20.1 (n=31) vs 16.0/12.6 months (n=11), HR: 0.43 (0.19-0.96, p=0.039)

Clinically Significant Adverse Events

Serious AE: none
Grade 3-4 AE: none


FANG vaccine shows encouraging anti-tumor activity and increased RFS with remarkable safety


Oh J et al. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Gynecol Oncol (2016) 143(3):504-510

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.